APR Medicube sales rise 85% at Amazon event

The company said Medicube ranked 13 products in Amazon U.S. beauty’s top 100 bestsellers, while in Europe it averaged more than 16 products in the top 100 across the U.K., Germany, Spain, Italy and France. That is a sharp step up from the roughly seven products that reached the ranking on the prior Prime Day, indicating broader assortment depth and stronger repeatability beyond a single hero SKU.

The timing is important. Prime Big Deal Days is one of the first major demand tests before Black Friday and Christmas, when consumer spending is most closely watched and inventory decisions are set. APR’s show of strength suggests it enters the peak season with real pricing power and improved brand awareness, especially in the U.S., where Medicube’s core products such as Zero Pore Pad, PDRN Pink Peptide Ampoule, PDRN Pink Collagen Gel Mask and Collagen Jelly Cream are gaining traction.

For investors, the thesis is straightforward: this is the kind of scaling event that can re-rate a consumer name if the company sustains international growth. The market often underestimates how quickly digitally native beauty brands can compound once they crack Amazon’s algorithm, build review depth and turn one-time buyers into loyal customers. A 85% U.S. sales surge is not just a promotional pop; it is evidence of a brand inflection point.

The opportunity now is execution. If APR can carry this momentum into Black Friday and year-end gifting, the company has a chance to convert a strong Amazon moment into lasting share gains in one of the fastest-growing corners of global beauty. The stock case hinges on whether this is the start of a multi-quarter international expansion story, not a one-event spike.